ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.296,42
1,32%
S&P 500
5.728,36
0,17%
US Dollar vs BRL
5,4562
-1,47%
Bitcoin
63.831,00
0,80%
Brent Oil
74,615
1,19%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Sanofi (SNY)

  7. Sanofi (SNY) Notícias

SNY

Sanofi (SNY)

Sanofi
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SNY
DataHoraFonteTítuloCódigoCompanhia
24/09/202415:51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
23/09/202407:32IH Market NewsApollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and MoreNASDAQ:SNYSanofi
20/09/202408:45GlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year OldNASDAQ:SNYSanofi
16/09/202409:00PR Newswire (US)Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDANASDAQ:SNYSanofi
13/09/202413:15GlobeNewswire Inc.Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)NASDAQ:SNYSanofi
12/09/202403:37Business WireSanofi, RadioMedix, and Orano Med Announce Licensing Agreement on Next-Generation Radioligand Medicine for Rare CancersNASDAQ:SNYSanofi
12/09/202403:37Business WireAccord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers raresNASDAQ:SNYSanofi
13/08/202410:06Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SNYSanofi
13/08/202407:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SNYSanofi
26/07/202413:08PR Newswire (Canada)Le vaccin FluzoneMD Haute Dose Quadrivalent demeure le vaccin préférentiellement recommandé pour protéger les adultes de 65 ans et plus contre la grippeNASDAQ:SNYSanofi
26/07/202412:17PR Newswire (Canada)Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenzaNASDAQ:SNYSanofi
25/07/202407:19IH Market NewsEarnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5%NASDAQ:SNYSanofi
10/07/202417:10PR Newswire (US)Sanofi ships U.S. influenza vaccines for the 2024/25 seasonNASDAQ:SNYSanofi
09/07/202407:54IH Market NewsBP Slashes Profit Forecast by $700 Million; Morgan Stanley Predicts S&P 500 10% Drop, and More NewsNASDAQ:SNYSanofi
26/06/202418:30GlobeNewswire Inc.Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of MedicineNASDAQ:SNYSanofi
06/06/202408:00PR Newswire (US)I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical OfficerNASDAQ:SNYSanofi
31/05/202417:30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SNYSanofi
31/05/202402:05GlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDNASDAQ:SNYSanofi
31/05/202402:00GlobeNewswire Inc.Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 InflammationNASDAQ:SNYSanofi
28/05/202411:34Edgar (US Regulatory)Form SD - Specialized disclosure reportNASDAQ:SNYSanofi
23/05/202408:40IH Market NewsOpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More NewsNASDAQ:SNYSanofi
21/05/202408:18IH Market NewsCalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More NewsNASDAQ:SNYSanofi
13/05/202402:00GlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)NASDAQ:SNYSanofi
10/05/202409:02IH Market NewsNovavax Surges 57% Post $1.4 Billion Sanofi Deal; Apple Boosts Data Centers with AI and Internal Chips, and More NewsNASDAQ:SNYSanofi
10/05/202403:00PR Newswire (US)Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination VaccinesNASDAQ:SNYSanofi
25/04/202408:52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNASDAQ:SNYSanofi
19/04/202408:31IH Market NewsParamount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and MoreNASDAQ:SNYSanofi
23/02/202416:02Edgar (US Regulatory)Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).NASDAQ:SNYSanofi
23/02/202413:15Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:SNYSanofi
14/02/202417:57Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNYSanofi
 Apresentando as notícias mais relevantes sobre:NASDAQ:SNY

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HAGA3
HAGA ON
BOV
COGN3
COGNA ON
BOV
AZEV4
AZEVEDO PN
BOV
GFSA3
GAFISA ON
BOV
AZUL4
AZUL PN
BOV
PDGR3
PDG REALT ON
BOV
OIBR3
OI ON
BOV
PRIO3
PETRORIO ON
BOV
JFEN3
JOAO FORTES ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
CBEE3
AMPLA ENERG ON
BOV
AGXY3
Agrogalaxy Participacoes ON
BOV
TELB4
TELEBRAS PN
BOV
RAIZ4
Raizen S.A PN
BOV
AMER3
Americanas ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados